Clinical Trial Update: Dose Ranging Study in Elective Total Hip Replacement Surgery [Phase 2, Phase 3]

View source ↗

Summary

A dose-ranging Phase 2/Phase 3 trial in elective total hip replacement surgery evaluated prevention of venous thromboembolism, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Snippet

Sponsor: Sanofi | Conditions: Venous Thromboembolism | Phase 2, Phase 3 | Status: COMPLETED